Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Ltd. is a pioneering Australian company specializing in the development of innovative treatments for UV and light-related skin disorders. Their flagship product, SCENESSE®, is the first systemic photoprotective drug approved for preventing phototoxicity in patients with erythropoietic protoporphyria. The company leverages its expertise in photomedicine and melanocortin peptides to address unmet medical needs globally.
Short position
Clinuvel Pharmaceuticals (ASX:CUV) has 9.07% of its shares on issue reported as short positions as of 5 Oct 2026, or about 4,572,694 shares. Over the past 30 days that figure has risen 0.96 percentage points, and over 90 days it has been broadly flat. Its highest recorded short interest was 10.04% in August 2020. CUV is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Clinuvel Pharmaceuticals (CUV) short interest history
CUV Short Interest History
- 30-day change
- +0.96pp
- 90-day change
- -0.03pp
- 1-year change
- +2.78pp
- All-time high
- 10.04% (August 2020)
- All-time low
- 0.00% (November 2016)
Is CUV heavily shorted?
CUV's short interest of 9.07% is elevated relative to the ASX average, ranking #19 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has CUV's short interest changed recently?
Over the past 30 days Clinuvel Pharmaceuticals's short interest has risen 0.96 percentage points, and over 90 days it has been broadly stable. The current level is 9.07% of shares on issue.
What is the highest CUV's short interest has been?
Since 2010, Clinuvel Pharmaceuticals's short interest peaked at 10.04% in August 2020 and bottomed at 0.00% in November 2016.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2010. See our methodology.